Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.

Publisher Website
Google Scholar
Abstract
Infection of cells of the Epstein-Barr virus (EBV)-negative human B[bone marrow derived]-lymphoma lines BJAB and Ramos with EBV preparations from [human lymphoma] P3HR-1 or B 95-8 cells converted these cells to EBV genome carriers expressing Epstein-Barr nuclear antigen (EBNA) in almost 100% of these cells. Induction of these cells and clones from P3HR-1 EBV-converted BJAB cells with iododeoxyuridine, aminopterin and hypoxanthine resulted in the appearance of a nuclear antigen in about 1-6% of the cells 1-4 days after induction. The antigen is different from known EBV-induced antigens like EBNA, viral capsid antigen (VCA) or the D- and R-subspecificities of the early antigen (EA) complex. It is demonstrated by indirect immunofluorescence and inactivated after acetone fixation. The antigen was not detectable after induction of uninfected BJAB and Ramos cells nor was it found in noninduced or induced P3HR-1 and [human lymphoma] Raji cells. Thus, it appears that EBV-infection mediates the expression of this antigen, for which the name TINA (transiently induced nuclear antigen) is suggested. Sera reacting against TINA generally contained high antibody titers against EBV-induced EA. Only a limited number of highly EA-reactive sera, were also positive for TINA. Among 200 sera tested thus far, TINA reactivity was most frequently observed in sera of patients with nasopharyngeal carcinoma (7 of 28), in sera of the only 2 patients with immunoblastoma tested and occasionally in sera from patients with Hodgkin''s disease and chronic lymphatic leukemia. Among 70 sera from nontumor patients, TINA reactivity was observed 3 times: 2 patients suffered from chronic infectious mononucleosis, the other revealed persistent splenomegaly.